What common adverse effect will the nurse assess in patients who are receiving cholinergic agents?

Choice A rationale Circulatory overload is generally associated with intravenous fluid mismanagement or renal failure rather than the standard pharmacological actions of cholinergic agents. These drugs primarily stimulate the parasympathetic nervous system by mimicking acetylcholine. While they can cause bradycardia or hypotension, they do not typically lead to the massive fluid volume expansion seen in circulatory overload. Therefore, this is not a priority assessment for patients receiving these specific medications for ocular or systemic issues. Choice B rationale Cholinergic agents, such as pilocarpine, act on the muscarinic receptors of the ciliary muscle and the sphincter pupillae, causing miosis or pupil constriction. This narrowing of the pupil reduces the amount of light entering the eye, which significantly impairs the patient's ability to see in low-light environments or at night. Nurses must educate patients on this safety risk, as reduced night vision increases the likelihood of falls and accidents in dimly lit areas. Choice C rationale Sensitivity to sulfonamides is a specific drug allergy unrelated to the mechanism of action of cholinergic drugs. Cholinergic agents do not share chemical structures with sulfonamide antibiotics, so a patient receiving a cholinergic drug would not automatically be at risk for a cross-reaction. Nursing assessments for allergies are important for all medications, but there is no physiological link between cholinergic therapy and sulfonamide hypersensitivity that would make this a common or expected adverse effect. Choice D rationale Bleeding tendencies are typically related to anticoagulants, antiplatelet therapy, or hematologic disorders rather than cholinergic stimulation. Cholinergic agents focus on enhancing parasympathetic activity, leading to effects like increased salivation, lacrimation, and smooth muscle contraction. They do not interfere with the coagulation cascade or platelet aggregation. Consequently, monitoring for signs of hemorrhage or prolonged clotting times is not a specific requirement when assessing a patient for the side effects of cholinergic medication therapy.